Effect the determination of L- carnitine replacement therapy for the maintenance hemodialysis patients with ESA resistance anemia (study of algorithms)
Not Applicable
Recruiting
- Conditions
- renal anemia
- Registration Number
- JPRN-jRCT1090220256
- Lead Sponsor
- shogo kimura
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
patients three times a week hemodialysis have received more than one year.
hemodialysis patients with no change over the past one month in the esa administration.
Patients with hb concentration of the past three months has remained at 12g/dL
fc is less than the normal value 40.0
Patients over 20 years old
Patient obtained a consent with respect to the present.
Exclusion Criteria
Patients with hypersensitivity to levocarnitine (Erukaruchin R)
Patients with obvious factors that influence the Hb concentration, such as moderate or severe infectious diseases, malignant tumor, hemorrhage, collagen disease, chronic liver disease, low-nutrition, and blood disease
Less than serum ferritin value is 100ng / mL
MCV is less than 90fL, more 105f
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method RBC, Hb,% retic, retic, TC, FC, AC value, AC in the blood cells, the length of the carbon chain
- Secondary Outcome Measures
Name Time Method Of hypersensitivity to levocarnitine (Erukaruchin R) patients, of obvious factors that influence the Hb concentration, such as moderate or severe infectious diseases, malignant tumor, hemorrhage, collagen disease, chronic liver disease, low-nutrition, and blood disease some patients, serum ferritin value is less than 100ng / mL, MCV is less than 90fL, more 105f